Myriad Genetics, MDS sales and marketing update

MDS expanded its exclusive marketing agreement with MYGN to include marketing in Canada of MYGN's Colaris diagnostic that detects mutations in two genes with predictive value for hereditary colorectal and uterine cancer. MDS exclusively markets MYGN's hereditary breast and ovarian cancer tests in Canada. ...